FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
REGULATED INFORMATION
GHENT, Belgium, Jan. 21, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 288,170 common shares have been issued by the Company in exchange for €1,192,292.70 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 55,100,544 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,528,657 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
Pdf version of the press release http://hugin.info/137912/R/1980185/725377.pdf
HUG#1980185
